Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 10Neoplasms 8Fallopian Tube Neoplasms 8Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Brain Neoplasms 4Astrocytoma 4Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Gliosarcoma 3Glioblastoma 3Colonic Neoplasms 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2

Interventions

adavosertib 2veliparib 1trametinib 1pamiparib 1cabozantinib 1Temozolomide 1Everolimus 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignant Solid Neoplasm × veliparib × Clear all
NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

National Cancer Institute (NCI)

Phase 2 Completed
208 enrolled 27 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡